If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following ...

Mid-cap stocks staged a strong recovery in the second quarter, rebounding from the broad drawdown at the beginning of the ...

Here’s what the HHS Secretary has achieved during his first six months in office — and what it means for pharma.